Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Non-US | 53.2 | 45.2 | 37.3 | | | | | |
| Medical Devices | 32.0 | 28.8 | 22.3 | 27.7 | | | | |
| Total international | | | | 45.0 | | | | |
| Non Us | | | | | 39.5 | 36.3 | | |
| Other | 245.2 | 200.3 | 146.9 | 158.1 | 162.1 | 138.4 | | |
| Total revenues | 330.4 | 274.3 | 206.5 | 230.8 | 201.6 | 174.7 | 155.1 | 129.8 |
| Revenue growth [+] | 20.4% | 32.8% | -10.5% | 14.5% | 15.4% | 12.6% | 19.5% | 20.8% |
| Non-US | 17.7% | 21.2% | | | | | | |
| Medical Devices | 11.3% | 29.1% | -19.5% | | | | | |
| Non Us | | | | | 8.7% | | | |
| United States | 21.0% | 35.4% | -8.9% | | | | 19.7% | 27.4% |
| Cost of goods sold | 84.4 | 68.5 | 57.2 | 60.5 | 0.8 | 0.9 | 44.0 | 36.9 |
| Gross profit | 245.9 | 205.9 | 149.3 | 170.3 | 200.8 | 173.8 | 111.1 | 92.9 |
| Gross margin | 74.4% | 75.0% | 72.3% | 73.8% | 99.6% | 99.5% | 71.6% | 71.6% |
| Selling, general and administrative | 231.3 | 204.6 | 150.8 | 167.1 | 164.2 | 151.1 | 106.4 | 93.9 |
| Research and development | 57.3 | 48.5 | 43.1 | 41.2 | | | 35.8 | 25.7 |
| EBITDA [+] | -31.0 | -36.9 | -35.0 | -28.7 | | | -21.8 | -20.4 |
| EBITDA growth | -16.0% | 5.2% | 22.2% | -178.3% | 61.4% | -203.8% | 6.8% | 76.4% |
| EBITDA margin | -9.4% | -13.4% | -17.0% | -12.4% | 18.2% | 13.0% | -14.1% | -15.8% |
| Depreciation | 8.1 | 7.5 | 7.9 | 7.4 | -1.5 | -1.4 | 7.7 | 5.0 |
| EBITA | -39.0 | -44.4 | -42.9 | -36.1 | 38.1 | 24.0 | -29.5 | -25.4 |
| EBITA margin | -11.8% | -16.2% | -20.8% | -15.6% | 18.9% | 13.8% | -19.0% | -19.6% |
| Amortization of intangibles | 3.7 | 2.9 | 1.7 | 1.9 | 1.5 | 1.4 | 1.6 | 1.3 |
| EBIT [+] | -42.7 | -47.3 | -44.6 | -38.0 | 36.6 | 22.7 | -31.1 | -26.7 |
| EBIT growth | -9.8% | 6.1% | 17.2% | -203.9% | 61.4% | -172.8% | 16.5% | 63.3% |
| EBIT margin | -12.9% | -17.2% | -21.6% | -16.5% | 18.2% | 13.0% | -20.1% | -20.6% |
| Non-recurring items [+] | | -102.5 | -0.4 | -4.9 | | | | |
| Asset impairment | | 82.3 | | | | | | |
| Loss on contingent liability | | -184.8 | -0.4 | -4.9 | | | | |
| Interest expense, net [+] | 3.0 | 4.5 | 3.8 | 1.7 | -1.0 | -0.2 | 1.6 | 0.1 |
| Interest expense | 5.0 | 4.9 | 4.9 | 4.1 | 4.6 | 2.3 | 1.8 | 0.3 |
| Interest income | 2.0 | 0.5 | 1.1 | 2.4 | 1.0 | 0.2 | 0.2 | 0.2 |
| Other income (expense), net [+] | -0.5 | -0.4 | 0.0 | -0.2 | -53.9 | -47.5 | -0.6 | -0.4 |
| Other | -0.5 | -0.4 | 0.0 | -0.2 | | | -0.6 | -0.4 |
| Pre-tax income | -46.2 | 50.4 | -48.0 | -35.0 | -20.9 | -26.9 | -33.3 | -27.2 |
| Income taxes | 0.3 | 0.2 | 0.1 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.4% | | | | | | |
| Net income | -46.5 | 50.2 | -48.2 | -35.2 | -21.1 | -26.9 | -33.3 | -27.2 |
| Net margin | -14.1% | 18.3% | -23.3% | -15.2% | -10.5% | -15.4% | -21.5% | -21.0% |
| |
| Basic EPS [+] | ($1.02) | $1.11 | ($1.14) | ($0.94) | ($0.62) | ($0.83) | ($1.05) | ($0.97) |
| Growth | -191.2% | -197.4% | 22.1% | 51.0% | -25.3% | -21.3% | 8.7% | 57.8% |
| Diluted EPS [+] | ($1.02) | $1.09 | ($1.14) | ($0.94) | ($0.62) | ($0.83) | ($1.05) | ($0.97) |
| Growth | -193.2% | -195.4% | 22.1% | 51.0% | -25.3% | -21.3% | 8.7% | 57.8% |
| |
| Shares outstanding (basic) [+] | 45.7 | 45.1 | 42.1 | 37.6 | 34.1 | 32.4 | 31.6 | 28.1 |
| Growth | 1.5% | 7.0% | 12.1% | 10.3% | 5.2% | 2.5% | 12.7% | 6.4% |
| Shares outstanding (diluted) [+] | 45.7 | 46.0 | 42.1 | 37.6 | 34.1 | 32.4 | 31.6 | 28.1 |
| Growth | -0.6% | 9.3% | 12.1% | 10.3% | 5.2% | 2.5% | 12.7% | 6.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|